EPON ph I, FIH Metastatic Gastric Cancer
People with Metastatic Gastric Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age
• Have functions of important organs
• Have HER2 expression or mutation must have a pathologically documented advanced/unresectable or metastatic solid tumor that is refractory to or intolerable with standard treatment
• Have a pathologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
• Have a pathologically documented advanced/unresectable or metastatic breast cancer with HER2 low expression
• Have a pathologically documented advanced/unresectable or metastatic NSCLC with HER2 expression or mutation
• Have a pathologically documented advanced/unresectable or metastatic cancer with HER2 expression or mutation
You may NOT participate in this study if you:
• Have received mitomycin C and nitrosoureas chemotherapy within 6 weeks before first time study drug administration
• Have Active central nervous system (CNS) metastasis without surgery or radiotherapy
• Have known immunodeficiency virus (HIV) infection, hepatitis B or C
• Any surgery (eg., surgery for cancer treatment), radiotherapy, chemotherapy or molecular targeted treatment within 4 weeks
• Have a history of clinically significant lung diseases
• Have a known history of severe allergy to any component of the SHR-A1811 product
• Are pregnant or breastfeeding
Contact Information
Mohammad Ghalib, Study Coordinator
1695 Eastchester Road, 2nd Floor
Bronx, NY 10461
Phone: (718) 405-8515
Email: MHGHALIB@MONTEFIORE.ORG